Tag

Eli Lilly and Co. has negotiated the right to market a knockoff version of the world’s top-selling insulin, Lantus. ( LLY ) said that it has entered into a settlement agreement to resolve patent litigation with Sanofi regarding its insulin glargine product, Basaglar.

Pharmaceutical company Sanofi announced on Monday that a second late-stage Phase III clinical trial of its new diabetes medication LixiLan had met its primary target.